Nuwacell Biotech Co., Ltd. was founded in 2016 and is dedicated to developing widely accessible iPSC-derived cell therapy products.

Our company has established a product and service system covering the entire industrial chain, including upstream iPSC technology (iPSC reprogramming for library construction and clinical-grade culture reagent products), mid-stream (iPSC-related CDMO/scientific research technical services), and downstream (development of iPSC-derived cell therapies). Our owns internationally leading high-standard R&D and production facilities for scientific research-grade and clinical-grade stem cells, as well as the largest iPSC bank of super donors from the Chinese population in China. Meanwhile, a portfolio of invention patents centered around iPSC technology applications has been systematically established, covering areas such as iPSC reprogramming, directed induction and differentiation of multiple functional cells, production processes, and key raw materials.

Centered on the core iPSC technology, Nuwacell continuously promotes the R&D of multiple cell drug pipelines in three major medical fields: anti-inflammatory repair, tumor immunology, and regenerative medicine. Currently, several product pipelines have entered the stage of registered clinical trials. Among them, NCR100 and NCR300 are the first iMSC and iNK cell products approved for clinical trials in China, and NCR101 is the world's first gene-modified iMSC cell product approved for clinical trials. The company's subsequent iPSC-derived cell therapies will also be successively submitted for IND applications to enter the clinical trial stage, continuously exploring the clinical value of iPSC-derived cell therapies.